Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Hengrui Pharmaceuticals (01276.HK) Subsidiary's HRS9531 Injection Approved to Commence Clinical Trials
Recommend 2 Positive 3 Negative 2 |
||||
|
||||
|
Hengrui Pharmaceuticals (01276.HK) announced that HRS9531 injection developed by its subsidiary Fujian Shengdi has been approved by the National Medical Products Administration to commence clinical trials in overweight and obese adolescent patients. The marketing application for HRS9531 for long-term weight management in adults was accepted by the National Medical Products Administration in September 2025. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
